Longevity Genes, Blood Biomarkers of Aging, & Targeting Aging with Metformin with Dr. Nir Barzilai
Mar 6, 2024
auto_awesome
Dr. Nir Barzilai discusses genetics, lifestyle, and blood biomarkers influencing healthspan and lifespan, with a focus on targeting aging using metformin. The episode explores centenarians, factors affecting longevity, gender disparities in aging research, proteomic biomarkers, and future gerosarapeutic candidates. Actionable insights on personalized health strategies and the evolution of longevity medicine are shared.
Centenarians experience a contraction of morbidity, delaying disease onset and focusing on healthspan over lifespan.
Dr. Barzilai's research in aging genetics influences targeting aging with metformin to extend healthspan and prevent age-related diseases.
Gender differences in protein biomarkers suggest women may live longer with more stable proteome changes, impacting overall organ health and aging status.
Deep dives
Centenarians Show Delayed Onset of Diseases
Centenarians compared to current people experience diseases 20-30 years later, showing a delay in disease onset known as 'contraction of morbidity'. This reveals a focus on health span in addition to the lifespan, demonstrating a short period of sickness at the end of their lives.
Dr. Barzilai's Research on Human Longevity Genetics
Dr. Barzilai's research in aging genetics, particularly in centenarian families, uncovers genes and factors delaying aging and protecting against age-related diseases. His studies have influenced drug development, like metformin, to delay aging's multi-morbidities. This research aims to extend human health span and prevent age-related diseases.
Gender Differences in Aging and Longevity Factors
Women generally live longer than men, possibly linked to more stable proteome changes during aging. This study found women have one-third more age-related proteins than men from ages 65 to 95. Protein biomarkers may indicate organ aging correlation with body age, reflecting organ health status in relation to overall aging.
Metformin: A Comprehensive Look at Its Impact
Metformin, originally used to treat arthritis and prevent flu and malaria, was found to lower glucose levels in diabetic patients, leading to its use for diabetes. Further studies revealed its wide-ranging benefits, including preventing diabetes, reducing cardiovascular disease, decreasing cancer risk, improving cognitive function, and impacting the hallmarks of aging. Metformin's impact on insulin sensitivity in the liver was significant, demonstrating its potential as a gerotherapeutic that addresses multiple health aspects.
GLP1 Agonist: A New Player in Longevity
GLP1 agonists, known for their effectiveness in diabetes and weight management, are emerging as potential tools for maximizing healthspan and longevity. These drugs not only aid in weight loss and diabetes management but also show promise in extending lifespan and reducing mortality. The combination of GLP1 agonists with other treatments like metformin could offer a holistic approach to health optimization, especially for individuals struggling with obesity or metabolic issues.
Aging is inevitable, but can we influence how we age? In this episode of Longevity by Design, hosts Dr. Gil Blander and Ashley Reaver, MS, RD, CSSD, interview Dr. Nir Barzilai—the Director of the Institute for Aging Research at the Albert Einstein College of Medicine and the Director of the Paul F. Glenn Center for the Biology of Human Aging Research and of the National Institutes of Health’s (NIH) Nathan Shock Centers of Excellence in the Basic Biology of Aging—during which he discusses groundbreaking research on aging.
This is an enlightening discussion with Dr. Barzilai on factors influencing healthspan and lifespan, and the paradigm-shifting idea of targeting aging to extend healthspan and lifespan. He shares fascinating insights from his research on the influence of genetics and lifestyle on healthspan and lifespan, and blood biomarkers of aging. The conversation sheds light on the emerging scientific evidence and paradigm-shifting concept for medical interventions (gerotherapeutics) to extend healthspan and lifespan by targeting the underlying biology of aging.
The episode wraps up with actionable insights for listeners interested in enhancing their healthspan and longevity. Dr. Barzilai discusses the importance of personalized health strategies, integrating cutting-edge research with everyday health practices while emphasizing the importance of a holistic approach. As a listener, you will leave equipped with knowledge and science-backed ways to navigate your personal health journey and help you live healthier longer.
Timestamps:
Introduction: 00:00-04:13
Why Dr. Barzilai’s studies centenarians and their children?: 04:14-10:07
Do centenarians live longer with poor health or live healthier longer? 10:08-13:07
Does becoming a centenarian have a strong genetic influence?: 13:08-15:41
How do growth hormone and IGF-1 affect healthspan and lifespan?: 15:32-23:39
What other genes affect healthspan and lifespan?: 23:40- 26:51
Does low IGF-1 negatively impact muscle and physical functioning?: 26:52-28:40
What are the effects of ethnicity and socioeconomic status on longevity: 28:41-30:57
What is the effect of lifestyle, nutrition, and exercise on the longevity of centenarians?: 30:58-34:07
Do women or men live longer?: 34:08-37:55
Why do women live longer than men?: 37:56-41:38
Biomarkers of aging and biomarkers of organ aging: 41:39-47:07
What is metformin, and what is the purpose of the TAME trial?: 47:08-51:37
Do you think metformin will improve healthspan and lifespan?: 51:38-54:20
Does metformin only improve blood glucose control, or does it benefit health and aging in other ways? 54:21-56:50
Is metformin good for older adults but not young adults?: 56:51-57:45
How does the combination of metformin and exercise impact muscle size (hypertrophy) and strength?: 57:46-01:00:45
Should everyone take metformin?: 01:00:46-01:03:13
Dr. Gil Blander’s and Dr. Nir Barzilai’s personal humorous anecdotes on exercise: 01:03:14-01:04:32
Is there a reason and explanation for why metformin did not show an effect on lifespan in mice in the Interventions Testing Program (ITP)?: 01:04:33-01:07:01
Are GLP-1 agonists beneficial for healthspan and lifespan?: 01:07:02-01:10:55
Are there tradeoffs with using GLP-1 agonists?: 01:10:56-01:11:43
What are the top 5 gerotherapeutic candidates for improving healthspan and lifespan?: 01:11:44-01:15:10
Dr. Nir Barzilai’s top tip for improving health: 01:15:11-01:19:29
Get the Snipd podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share & Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode